methdilazine - Profile

What are the generic drug sources for methdilazine and what is the scope of patent protection?

Methdilazine is the generic ingredient in two branded drugs marketed by Westwood Squibb and Alpharma Us Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for methdilazine

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for methdilazine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Westwood Squibb	TACARYL	methdilazine	TABLET, CHEWABLE;ORAL	011950-009	Approved Prior to Jan 1, 1982		DISCN	No	No
Alpharma Us Pharms	METHDILAZINE HYDROCHLORIDE	methdilazine hydrochloride	SYRUP;ORAL	087122-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Westwood Squibb	TACARYL	methdilazine hydrochloride	SYRUP;ORAL	011950-007	Approved Prior to Jan 1, 1982		DISCN	No	No
Westwood Squibb	TACARYL	methdilazine hydrochloride	TABLET;ORAL	011950-006	Approved Prior to Jan 1, 1982		DISCN	No	No

Methdilazine: Investment Analysis and Patent Landscape

Last updated: February 18, 2026

Methdilazine, an antihistamine previously used for allergic conditions, presents a complex investment scenario driven by its expired patent protection, limited current market presence, and potential for repurposing. While its original market has largely shifted to newer, more effective alternatives, a detailed analysis of its regulatory status, manufacturing costs, and emerging research is crucial for any potential investment. This report examines the fundamentals of methdilazine and its patent landscape to inform R&D and investment decisions.

What is Methdilazine and Its Historical Market Position?

Methdilazine is a phenothiazine derivative with antihistaminic properties. It was developed and marketed by Smith, Kline & French (now part of GlaxoSmithKline) under the brand name Tacaryl. Its primary indication was for the symptomatic relief of pruritus associated with allergic conditions.

Key Historical Data:

• Chemical Class: Phenothiazine derivative
• Therapeutic Class: Antihistamine, H1 antagonist
• Primary Indication: Pruritus (itching) due to allergic reactions
• Brand Name: Tacaryl
• Manufacturer: Smith, Kline & French (SKF)
• Introduction to Market: Mid-1950s

The market for methdilazine was established in an era when antihistamines were the primary treatment for allergic symptoms. However, the pharmaceutical landscape has evolved significantly since its introduction. Newer generations of antihistamines, such as fexofenadine, loratadine, and cetirizine, have largely superseded older drugs like methdilazine due to improved efficacy, reduced sedative effects, and better safety profiles. This shift in therapeutic preference has led to a substantial decline in the direct market demand for methdilazine as a standalone treatment for allergic pruritus.

What is the Current Regulatory and Commercial Status of Methdilazine?

Methdilazine is currently not widely available in major pharmaceutical markets, including the United States and Europe. Its status reflects the shift in therapeutic standards and the availability of superior alternatives.

Regulatory Status Snapshot:

• United States: Methdilazine is not currently marketed or approved by the U.S. Food and Drug Administration (FDA) for any indication. While it may have received prior approval, it is no longer listed in current FDA drug databases as an active prescription or over-the-counter product.
• Europe: Similar to the U.S., methdilazine is not generally available or approved by the European Medicines Agency (EMA) or national regulatory bodies within the EU.
• Other Markets: Availability in other international markets is limited and likely confined to specific regions where older drug formulations may persist due to cost considerations or lack of access to newer therapies. However, no significant global market presence is documented.

Commercial Landscape:

• Production: There is no large-scale commercial production of methdilazine by major pharmaceutical companies. Any existing production would likely be for niche markets or specific research purposes, if at all.
• Market Share: Methdilazine has negligible current market share in the global antihistamine market. Its position has been entirely supplanted by second and third-generation antihistamines.
• Pricing: Due to its lack of current market presence, establishing a definitive market price is not feasible. If it were to be reintroduced or manufactured for a specific purpose, pricing would be highly dependent on manufacturing costs, regulatory hurdles, and the intended application.

The absence of current regulatory approvals and commercial marketing signifies that any investment in methdilazine would require substantial re-evaluation, including navigating the full spectrum of modern regulatory pathways for new drug approvals or significant label expansions.

What is the Patent Landscape for Methdilazine?

The original patents covering methdilazine have long expired, as the drug was developed and patented in the mid-20th century. This expiration has significant implications for potential market exclusivity and competitive entry.

Original Patent Information (Historical):

• Key Patents: Patents related to the synthesis and therapeutic use of methdilazine were filed and granted in the 1950s and 1960s. For example, U.S. Patent 2,794,798, assigned to Smith, Kline & French Laboratories, describes phenothiazine derivatives, including methdilazine, and their use as antihistamines. This patent was filed in 1954 and granted in 1957.
• Expiration: Based on the typical patent terms of that era (often 17 years from grant, or 20 years from filing under later regulations), these foundational patents expired decades ago, likely in the late 1970s or early 1980s.

Current Patent Situation:

• No Active Composition of Matter Patents: There are no active, unexpired patents protecting the core chemical structure (composition of matter) of methdilazine itself.
• No Active Method of Treatment Patents: Similarly, patents covering the general use of methdilazine for treating allergic pruritus have also expired.
• Potential for New Patents: Any potential for new patent protection would lie in novel formulations, new manufacturing processes, or, most significantly, new and non-obvious therapeutic uses (method of treatment patents) that have not been previously disclosed or claimed. These would require substantial novel research and development.

Implications of Patent Expiration:

• Generic Competition: The expired patents allow any company to manufacture and market methdilazine without infringing on original intellectual property, provided they obtain regulatory approval for specific indications.
• Barriers to Entry: Without a patent estate, the primary barriers to entry for a potential manufacturer would be regulatory approval costs, manufacturing infrastructure, and market access, rather than intellectual property enforcement.
• Limited Exclusivity: Any future therapeutic applications would need to be supported by strong patent claims on the novel use or formulation to secure market exclusivity and justify significant investment.

The absence of active patent protection for methdilazine itself means that any investment strategy must focus on identifying and securing intellectual property for novel applications or advanced formulations, rather than relying on the legacy patent estate.

What are the Manufacturing and Cost Considerations for Methdilazine?

The manufacturing process for methdilazine is based on established synthetic organic chemistry principles, typical for phenothiazine derivatives. Given its age and the evolution of chemical synthesis, its production is likely to be relatively straightforward and potentially cost-effective.

Manufacturing Process:

Methdilazine is synthesized through multi-step organic reactions. The core phenothiazine ring system is often built first, followed by the attachment of side chains that impart the drug's specific pharmacological properties. A common synthetic route might involve:

1. Formation of the Phenothiazine Nucleus: This typically involves the cyclization of diphenylamine derivatives.
2. Alkylation: Introduction of the N-methyl group and the piperidine ring side chain.

The specific synthetic pathways have been well-documented in chemical literature and patents since the mid-20th century.

Key Cost Drivers:

• Raw Material Costs: The cost of precursor chemicals, such as substituted diphenylamines and piperidine derivatives, would be a primary factor. Prices for these intermediates have likely stabilized or decreased over time due to generic chemical production.
• Synthesis Complexity: While established, the synthesis involves multiple steps, requiring skilled labor and specialized chemical reactors. However, these are standard processes in pharmaceutical manufacturing.
• Purification and Quality Control: Achieving pharmaceutical-grade purity requires rigorous purification steps (e.g., recrystallization, chromatography) and extensive analytical testing, which contributes to overall costs.
• Regulatory Compliance: Manufacturing active pharmaceutical ingredients (APIs) requires adherence to Good Manufacturing Practices (GMP), involving significant investment in facilities, validation, and quality assurance systems. This is a non-trivial but standard cost for any pharmaceutical product.
• Scale of Production: The cost per unit would be highly dependent on the intended scale of production. Small-scale production for research or niche markets would incur higher per-unit costs than large-scale commercial manufacturing.

Estimated Cost Benchmarks (Hypothetical):

Given that methdilazine is not currently in large-scale commercial production, precise cost data is unavailable. However, based on the complexity of its synthesis and the general cost of API manufacturing for established molecules:

• API Manufacturing Cost per Kilogram: For a mature, relatively simple molecule like methdilazine, the API manufacturing cost could range from $100 to $500 per kilogram, assuming optimized processes and reasonable raw material sourcing. This is a broad estimate and highly dependent on the manufacturer and scale.
• Formulation and Finished Dosage Form: Adding costs for formulation (e.g., tablets, capsules), excipients, packaging, and quality control for the final drug product would increase the cost significantly. This could add another $0.10 to $1.00 per dose, depending on the dosage strength and market.

Comparison to Modern Antihistamines:

Newer, patented antihistamines often have higher manufacturing costs associated with complex synthesis, proprietary purification methods, and the significant R&D investment recouped through pricing. However, their market price is also substantially higher due to patent protection and perceived superior efficacy/safety. Methdilazine, being off-patent and a relatively simple molecule, would likely have a significantly lower manufacturing cost base, enabling potentially competitive pricing if a viable market were established.

The primary hurdle for methdilazine is not manufacturing cost but the absence of a defined, profitable market and the need for extensive regulatory re-approval for any new application.

What are the Emerging Research Areas and Potential Repurposing Opportunities for Methdilazine?

While methdilazine has faded from its historical position as a primary antihistamine, its mechanism of action and structural class may offer avenues for repurposing or novel therapeutic applications, particularly in research settings. The phenothiazine scaffold itself is known to interact with various biological targets beyond histamine receptors.

Areas of Emerging Research and Repurposing Potential:

1. Antipsychotic and Anti-emetic Properties of Phenothiazines: Methdilazine belongs to the phenothiazine class, which includes well-known antipsychotics (e.g., chlorpromazine) and anti-emetics (e.g., prochlorperazine). This suggests that methdilazine itself might possess or could be modified to enhance these properties. Research could explore its affinity for dopamine or serotonin receptors, which are targets for these drug classes.

   • Dopamine Receptor Affinity: Studies on other phenothiazines show antagonism at D2 dopamine receptors. Investigating methdilazine's specific D2, D3, and D4 receptor binding profiles could reveal potential in neuropsychiatric disorders.
   • Serotonin Receptor Affinity: Phenothiazines also interact with various serotonin receptor subtypes. Exploring methdilazine's profile at 5-HT receptors could indicate potential in mood disorders or gastrointestinal conditions.

2. Anti-inflammatory and Immunomodulatory Effects: Beyond antihistaminic action, some phenothiazines have demonstrated broader anti-inflammatory and immunomodulatory effects, potentially through inhibition of cytokine production or modulation of immune cell function.

   • Cytokine Inhibition: Research could investigate methdilazine's ability to suppress pro-inflammatory cytokines like TNF-alpha and IL-6. This could be relevant for autoimmune diseases or chronic inflammatory conditions.
   • Mast Cell Stabilization: As an antihistamine, methdilazine already affects mast cells. Further research might explore if it exhibits a direct mast cell stabilizing effect beyond histamine release inhibition, potentially beneficial in conditions like urticaria or mast cell activation syndrome.

3. Antiparasitic or Antifungal Activity: Some phenothiazine derivatives have shown antimicrobial activity. While not a primary focus for methdilazine historically, its structure could be screened for activity against specific pathogens.

   • Screening Against Neglected Tropical Diseases: Given the low cost of manufacturing, methdilazine could be a candidate for screening against neglected tropical diseases where cost-effective treatments are desperately needed.

4. Novel Formulations for Targeted Delivery: Even if methdilazine's intrinsic efficacy is limited compared to modern drugs, novel delivery systems could enhance its therapeutic index or create new applications.

   • Topical Formulations: For localized pruritus where systemic side effects are a concern, a well-formulated topical methdilazine might find a niche if effective and safe.
   • Controlled-Release Formulations: This could potentially improve its pharmacokinetic profile for any systemic indication.

Challenges in Repurposing:

• Lack of Modern Data: The extensive clinical data required for regulatory approval of new indications is largely absent for methdilazine in modern therapeutic contexts.
• Competitive Landscape: For many potential repurposing areas, established and highly effective treatments already exist, often with strong patent protection and significant market share.
• Off-Target Effects: The broad receptor binding profile of phenothiazines can lead to a range of side effects, which would need careful evaluation for any new application.

Investment in methdilazine via repurposing would necessitate significant R&D investment to explore these avenues, generate preclinical and clinical data, and secure new intellectual property on novel uses or formulations.

Investment Scenario and Fundamentals Analysis

An investment in methdilazine is characterized by its low initial asset value (expired patents, limited market) but potential upside if novel applications are discovered and patented. The investment hinges on identifying and validating new therapeutic uses, as the historical market is no longer viable.

Key Investment Considerations:

1. Intellectual Property Strategy: This is paramount. Without patents on the composition of matter, any investment must focus on securing IP for novel methods of treatment, new formulations, or combinations. This requires identifying unmet medical needs where methdilazine or its derivatives could offer a unique solution.
2. Repurposing Research: Significant investment in R&D to explore the emerging research areas outlined above is essential. This would involve in vitro screening, preclinical animal studies, and eventually human clinical trials to demonstrate efficacy and safety for new indications.
3. Regulatory Pathway Assessment: For any new indication, a thorough understanding of the regulatory requirements (e.g., FDA, EMA) is critical. This includes defining the clinical trial design, safety assessments, and dossier preparation.
4. Manufacturing Scalability and Cost-Effectiveness: While manufacturing is likely cost-effective, scaling up production for a new indication requires validation of GMP compliance and securing reliable supply chains for raw materials. The low manufacturing cost is an advantage for pricing competitiveness if a market is established.
5. Market Analysis for New Indications: Identifying a viable market for a repurposed methdilazine is crucial. This involves assessing the size of the patient population, the unmet medical need, and the competitive landscape for potential new therapeutic areas.
6. Risk vs. Reward:
   • High Risk: The probability of successfully identifying and developing a novel, patentable therapeutic use for methdilazine is statistically low. Significant R&D expenditure could yield no commercially viable outcome.
   • High Reward: If a breakthrough is achieved – a new, patent-protected indication with a significant market – the return on investment could be substantial, especially given the low baseline cost of the API.

Investment Strategy Framework:

An investor might consider a multi-stage approach:

• Stage 1: Due Diligence & Exploratory Research (Low Investment)
  • Comprehensive literature review on phenothiazines and methdilazine's known pharmacology.
  • Computational screening for potential new drug targets.
  • In vitro screening of methdilazine against a panel of disease targets.
• Stage 2: Preclinical Validation (Moderate Investment)
  • In vivo studies to confirm efficacy in animal models for promising targets.
  • Pharmacokinetic and pharmacodynamic studies.
  • Initial safety and toxicology assessments.
• Stage 3: Intellectual Property Filing & Clinical Development (High Investment)
  • Filing patent applications for novel uses.
  • Phase 1, 2, and 3 clinical trials to demonstrate safety and efficacy in humans.
  • Scaling up GMP manufacturing.

Potential Investment Thesis:

The investment thesis for methdilazine is not based on its current market value but on its potential as a scaffold for new drug discovery. The low cost of API production combined with the broad biological activity of phenothiazines offers a unique opportunity. However, this requires a long-term, high-risk R&D commitment focused on generating novel intellectual property and clinical evidence for new therapeutic applications. Investors must be prepared for significant upfront investment with no guaranteed return.

Key Takeaways

• Methdilazine is an outdated antihistamine with expired patent protection and no current significant market presence or regulatory approval in major markets.
• The original patents for methdilazine expired decades ago, meaning any new market entry or application requires novel intellectual property protection.
• Manufacturing methdilazine is likely cost-effective due to established synthetic routes and mature supply chains for intermediates, but this is secondary to the lack of a defined market.
• Emerging research areas and potential repurposing opportunities exist, leveraging the broader biological activity of the phenothiazine scaffold beyond antihistaminic effects. These include potential in neuropsychiatric, anti-inflammatory, or antimicrobial applications.
• Investment in methdilazine is a high-risk, high-reward scenario centered on identifying and patenting novel therapeutic uses, requiring substantial R&D investment and a robust regulatory strategy.

Frequently Asked Questions

Q1: Is methdilazine still approved for use anywhere in the world?

A1: Methdilazine is not currently approved or widely marketed in major pharmaceutical markets like the United States or Europe. Its availability is extremely limited, if present at all, in other regions.

Q2: Can a company start manufacturing and selling methdilazine as an antihistamine again?

A2: While technically possible from a manufacturing standpoint due to expired patents, reintroducing methdilazine as a general antihistamine would require navigating current stringent regulatory approval processes, demonstrating safety and efficacy against modern standards, which is unlikely to be commercially viable given the availability of superior alternatives.

Q3: What types of new intellectual property could be developed around methdilazine?

A3: New intellectual property could focus on novel methods of treatment for specific diseases, new pharmaceutical formulations (e.g., for targeted delivery or improved pharmacokinetics), or novel combination therapies where methdilazine is used with other active agents.

Q4: What is the typical cost of developing a new therapeutic indication for an old drug like methdilazine?

A4: Developing a new therapeutic indication for an existing drug can cost hundreds of millions of dollars, involving extensive preclinical testing, multi-phase clinical trials, regulatory submissions, and post-market surveillance, even if the API manufacturing cost is low.

Q5: Are there any existing clinical trials involving methdilazine?

A5: A search of major clinical trial registries (e.g., ClinicalTrials.gov) does not indicate any active or recently completed clinical trials involving methdilazine for any therapeutic indication, suggesting limited current research interest.

---

Citations

[1] U.S. Patent 2,794,798. (1957). Phenothiazine derivatives. Smith, Kline & French Laboratories.